Think Tank on TROP-2 Therapy in NSCLC: A Look to the Future

Get up to date on emerging TROP-2–targeted antibody–drug conjugates for the treatment of advanced NSCLC with this comprehensive educational program, including expert-authored commentaries, a text module with a downloadable slideset capturing a panel discussion among 5 lung cancer experts, and a guided infographic on adverse event management with these agents.

Share

Program Content

Activities

Call to Action: TROP2 ADCs in Lung Cancer
Call to Action: Misperceptions on TROP2-Targeted Antibody–Drug Conjugates in Lung Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2023

Expires: February 23, 2024

TROP2 ADC + IO in NSCLC
Combination Therapy With TROP2-Targeted Antibody–Drug Conjugates and Immunotherapy in Advanced/Metastatic NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 03, 2023

TROP2 ADCs for NSCLC 2023
Progress in the Development of Antibody–Drug Conjugates Targeting TROP-2 for Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2023

Activities

TROP-2 in NSCLC
Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2023

Expires: July 24, 2024

TROP-2 ADCs
Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2023

Activities

TROP2 ADC Toxicities
Managing the Toxicities of TROP2 Antibody–Drug Conjugates in Lung Cancer
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2023

TROP-2 ADC Toxicities Guided Infographic
Managing the Toxicities of TROP-2 Antibody‒Drug Conjugates in Lung Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Provided by

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.